ctDNA-guided chemotherapy strategy misses primary endpoint but reduces neurotoxicity

◆ TRIAL DATA

The phase 2 PEGASUS trial in 135 patients with high-risk stage II/III colon cancer used serial ctDNA testing to guide treatment intensity; 3-year disease-free survival was 58.4% in ctDNA-positive patients versus 82.8% in ctDNA-negative patients, though the strategy reduced neurotoxicity compared to historical controls. (Nature Cancer)